Goldman Sachs’s Entrada Therapeutics TRDA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.69M Buy
212,780
+7,607
+4% +$87.2K ﹤0.01% 4265
2025
Q4
$2.11M Sell
205,173
-17,163
-8% -$145K ﹤0.01% 4540
2025
Q3
$1.29M Buy
222,336
+138,186
+164% +$808K ﹤0.01% 4853
2025
Q2
$565K Sell
84,150
-8,390
-9% -$67.5K ﹤0.01% 5090
2025
Q1
$837K Sell
92,540
-192,732
-68% -$2.4M ﹤0.01% 4823
2024
Q4
$4.93M Buy
285,272
+200,806
+238% +$3.64M ﹤0.01% 3468
2024
Q3
$1.35M Buy
84,466
+51,164
+154% +$806K ﹤0.01% 4433
2024
Q2
$475K Buy
33,302
+15,979
+92% +$227K ﹤0.01% 4864
2024
Q1
$245K Sell
17,323
-741
-4% -$10.5K ﹤0.01% 5045
2023
Q4
$273K Buy
18,064
+5,260
+41% +$77.9K ﹤0.01% 5045
2023
Q3
$202K Sell
12,804
-8,532
-40% -$134K ﹤0.01% 5043
2023
Q2
$323K Sell
21,336
-25,840
-55% -$356K ﹤0.01% 4979
2023
Q1
$684K Sell
47,176
-354,863
-88% -$4.74M ﹤0.01% 4645
2022
Q4
$5.44M Sell
402,039
-47,954
-11% -$841K ﹤0.01% 3090
2022
Q3
$7.09M Buy
449,993
+4,307
+1% +$54.7K ﹤0.01% 2831
2022
Q2
$5.43M Buy
445,686
+231
+0.1% +$1.75K ﹤0.01% 3062
2022
Q1
$4.18M Hold
445,455
﹤0.01% 3509
2021
Q4
$7.63M Buy
+445,455
New +$10.8M ﹤0.01% 3009

Other funds holding TRDA